Worth reading
58In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
46.7
Year-on-year change in operating profit (%)Wording
Conditional
How definitive the wording is.Results for this period
First quarter1 January 2026 to 31 March 2026ConsolidatedJapanese GAAPNet Sales33,665¥ millionYear on year +3.2%Progress 19.5%
Operating profit1,350¥ millionYear on year -46.7%Progress 10.8%
Ordinary income1,671¥ millionYear on year -30.4%Progress 12.9%
Net income attributable to owners of the parent1,036¥ millionYear on year -36.2%Progress 10.4%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share¥13.95
Financial position at period-end
Total assets254,864¥ million
of which net assets 208,926 ¥ millionEquity ratio 81.7%vs. prior year-end +5.4pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Segment revenueDomestic Business ¥24,437 million (YoY +3.8%), International Business ¥10,558 million (YoY +4.6%)
Segment profitDomestic Business ¥1,684 million (YoY -33.7%), International Business ¥-338 million
Regional salesRegion Japan / Net Sales for the Current Period ¥23,462 million / Net sales in the same period of the previous year ¥22,898 million, Region United States / Net Sales for the Current Period ¥4,404 million / Net sales in the same period of the previous year ¥4,837 million, Region China / Net Sales for the Current Period ¥2,662 million / Net sales in the same period of the previous year ¥1,992 million, Region Southeast Asia / Net Sales for the Current Period ¥2,013 million / Net sales in the same period of the previous year ¥2,038 million, Region Other / Net Sales for the Current Period ¥1,123 million / Net sales in the same period of the previous year ¥839 million
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥173,000 million (YoY +4.4%)
Operating profit¥12,500 million (YoY -16.2%)
Ordinary income¥13,000 million (YoY -23.5%)
Net income¥10,000 million (YoY +173.5%)
Annual Dividend Forecast¥104 → ¥106
Factors Behind Changes in Business Performance
Sales in the domestic business are recovering, supported by the launch of new products and continued marketing activities. In the international business, supply issues affecting healthcare-related products in the United States and weak demand in Southeast Asia were factors behind the decline in sales, while sales of Kairo, Netsusama Sheet and Ammeltz were strong in China.
Disclosure regarding the going concern assumption
Not applicable (no matters to report in the notes on the going concern assumption)
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNo material changes (no additions or exclusions)
Material subsequent eventsNo applicable matters.
Breakdown of extraordinary income (loss)Extraordinary income Gain on sale of non-current assets ¥0 million, Gain on sale of investment securities ¥461 million, Other ¥5 million / Extraordinary loss Losses on disposal of fixed assets ¥19 million, Product Recall-Related Losses ¥318 million, Other ¥62 million
Depreciation and amortization¥1,896 million
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingAvailable (for institutional investors and analysts)
Issued Shares at Period-End78,050,000 Shares
Treasury Shares at Period-End3,711,236 Shares
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 January 2026 to 31 March 2026 |
| Net Sales | ¥33,665 million (YoY +3.2%) |
| Operating profit | ¥1,350 million (YoY -46.7%) |
| Ordinary income | ¥1,671 million (YoY -30.4%) |
| Profit attributable to owners of the parent | ¥1,036 million (YoY -36.2%) |
| Net income per share | ¥13.95 |
| Equity ratio | End of the current fiscal period 81.7 / End of previous period 76.3 |
| Total assets | ¥254,864 million |
| Net assets | ¥208,926 million |
| Full-year earnings forecast | Net Sales ¥173,000 million (YoY +4.4%) / Operating profit ¥12,500 million (YoY -16.2%) / Ordinary income ¥13,000 million (YoY -23.5%) / Net income ¥10,000 million (YoY +173.5%) |
| Annual Dividend Forecast | ¥104 → ¥106 |
| Segment revenue | Domestic Business ¥24,437 million (YoY +3.8%), International Business ¥10,558 million (YoY +4.6%) |
| Segment profit | Domestic Business ¥1,684 million (YoY -33.7%), International Business ¥-338 million |
| Regional sales | Region Japan / Net Sales for the Current Period ¥23,462 million / Net sales in the same period of the previous year ¥22,898 million, Region United States / Net Sales for the Current Period ¥4,404 million / Net sales in the same period of the previous year ¥4,837 million, Region China / Net Sales for the Current Period ¥2,662 million / Net sales in the same period of the previous year ¥1,992 million, Region Southeast Asia / Net Sales for the Current Period ¥2,013 million / Net sales in the same period of the previous year ¥2,038 million, Region Other / Net Sales for the Current Period ¥1,123 million / Net sales in the same period of the previous year ¥839 million |
| Depreciation and amortization | ¥1,896 million |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥0 million, Gain on sale of investment securities ¥461 million, Other ¥5 million / Extraordinary loss Losses on disposal of fixed assets ¥19 million, Product Recall-Related Losses ¥318 million, Other ¥62 million |
| Disclosure regarding the going concern assumption | Not applicable (no matters to report in the notes on the going concern assumption) |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | No material changes (no additions or exclusions) |
| Material subsequent events | No applicable matters. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Available (for institutional investors and analysts) |
| Issued Shares at Period-End | 78,050,000 Shares |
| Treasury Shares at Period-End | 3,711,236 Shares |
| Factors Behind Changes in Business Performance | Sales in the domestic business are recovering, supported by the launch of new products and continued marketing activities. In the international business, supply issues affecting healthcare-related products in the United States and weak demand in Southeast Asia were factors behind the decline in sales, while sales of Kairo, Netsusama Sheet and Ammeltz were strong in China. |
Items this document does not state (10)
Operating MarginCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodRevision to Earnings ForecastPayout ratioShareholder Return PolicyOrders received and order backlogImpairment loss
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company cited the launch of new products and marketing activities in its domestic business, and strong sales of its core products in China in its international business, as factors behind the increase in sales. On the other hand, it cited supply issues affecting healthcare-related products in the United States and weak demand in Southeast Asia following the end of the infectious disease outbreak in the previous year. The company stated that the impact of the situation in the Middle East on results for the quarter was minor.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.